{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:13:37Z","timestamp":1790806417479,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijid.2026.108581","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:35:44Z","timestamp":1774283744000},"page":"108581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Phage therapy in people with cystic fibrosis: A systematic review"],"prefix":"10.1016","volume":"167","author":[{"given":"Vito","family":"Terlizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Rinninella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Viglietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"D\u2019Agosto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Di Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miqu\u00e9ias","family":"Lopes-Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Chiappini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijid.2026.108581_bib0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: from molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat Rev Genet"},{"issue":"10059","key":"10.1016\/j.ijid.2026.108581_bib0002","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet L Engl"},{"issue":"3","key":"10.1016\/j.ijid.2026.108581_bib0003","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/cei.13624","article-title":"Chronic bacterial pulmonary infections in advanced cystic fibrosis differently affect the level of sputum neutrophil elastase, IL-8 and IL-6","volume":"205","author":"Majka","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ijid.2026.108581_bib0004","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3389\/fmicb.2019.00913","article-title":"Tolerance and resistance of Pseudomonas aeruginosa biofilms to antimicrobial agents-how P. aeruginosa can escape antibiotics","volume":"10","author":"Ciofu","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijid.2026.108581_bib0005","unstructured":"160518_Final paper_with cover.Pdf. accessed 14 September 2025. Available from: https:\/\/amr-review.org\/sites\/default\/files\/160518_Final%20paper_with%20cover.pdf"},{"issue":"129","key":"10.1016\/j.ijid.2026.108581_bib0006","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1183\/09059180.00006512","article-title":"Treatment of pulmonary exacerbations in cystic fibrosis","volume":"22","author":"Bhatt","year":"2013","journal-title":"Eur Respir Rev J Eur Respir Soc"},{"issue":"6","key":"10.1016\/j.ijid.2026.108581_bib0007","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jcf.2017.06.012","article-title":"The potential of phage therapy in cystic fibrosis: essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways","volume":"16","author":"Trend","year":"2017","journal-title":"J Cyst Fibros J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.ijid.2026.108581_bib0008","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-1-4939-7604-1_11","article-title":"Phage therapy: various perspectives on how to improve the art","volume":"1734","author":"Abedon","year":"2018","journal-title":"Methods Mol Biol Clifton NJ"},{"issue":"10","key":"10.1016\/j.ijid.2026.108581_bib0009","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3390\/antibiotics13100926","article-title":"Mycobacteriophages and their applications","volume":"13","author":"Bonacorsi","year":"2024","journal-title":"Antibiot (Basel)"},{"issue":"3","key":"10.1016\/j.ijid.2026.108581_bib0010","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MCP.0000000000000864","article-title":"Advancing bacteriophages as a treatment of antibiotic-resistant bacterial pulmonary infections","volume":"28","author":"Satta","year":"2022","journal-title":"Curr Opin Pulm Med"},{"issue":"6","key":"10.1016\/j.ijid.2026.108581_bib0011","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.ijantimicag.2018.09.006","article-title":"Bacteriophage Sb-1 enhances antibiotic activity against biofilm, degrades exopolysaccharide matrix and targets persisters of Staphylococcus aureus","volume":"52","author":"Tkhilaishvili","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"10.1016\/j.ijid.2026.108581_bib0012","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70956","article-title":"Combined forces against bacteria: phages and antibiotics","volume":"8","author":"Afrasiabi","year":"2025","journal-title":"Health Sci Rep"},{"issue":"9","key":"10.1016\/j.ijid.2026.108581_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.05.017","article-title":"Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients","volume":"5","author":"Bernab\u00e9u-Gimeno","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.ijid.2026.108581_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.03.001","article-title":"Anti-inflammatory activity of Pseudomonas aeruginosa DEV phage in cystic fibrosis models","author":"Cafora","year":"2025","journal-title":"J Cyst Fibros J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.ijid.2026.108581_bib0015","article-title":"Phage therapy in the management of respiratory and pulmonary infections: a systematic review","volume":"12","author":"Sarkodie-Addo","year":"2025","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.ijid.2026.108581_bib0016","doi-asserted-by":"crossref","unstructured":"van den Berg DF, Brouns SJJ Reduced prevalence of phage defense systems in Pseudomonas aeruginosa strains from cystic fibrosis patients. mBio. 16(4):e03548\u201324. doi: 10.1128\/mbio.03548-24.","DOI":"10.1128\/mbio.03548-24"},{"key":"10.1016\/j.ijid.2026.108581_bib0017","unstructured":"CASP-checklist-randomised-controlled-trials-RCT-2024.Pdf. [accessed September 14 2025]. Available from: https:\/\/casp-uk.net\/casp-checklists\/CASP-checklist-randomised-controlled-trials-RCT-2024.pdf"},{"key":"10.1016\/j.ijid.2026.108581_bib0018","unstructured":"Martin J \u00a9 Joanna Briggs Institute 2017 critical appraisal checklist for case reports. 2017; https:\/\/jbi.global\/sites\/default\/files\/2019-05\/JBI_Critical_Appraisal-Checklist_for_Case_Reports2017_0.pdf"},{"key":"10.1016\/j.ijid.2026.108581_bib0019","unstructured":"Martin J \u00a9 Joanna Briggs Institute 2017 critical appraisal checklist for case series. 2017; https:\/\/jbi.global\/sites\/default\/files\/2019-05\/JBI_Critical_Appraisal-Checklist_for_Case_Series2017_0.pdf"},{"issue":"1","key":"10.1016\/j.ijid.2026.108581_bib0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cid\/ciac453","article-title":"Phage therapy of mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease","volume":"76","author":"Dedrick","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108581_bib0021","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.ijid.2026.108581_bib0022","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ijid.2026.108581_bib0023","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41591-025-03678-8","article-title":"Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis","volume":"31","author":"Chan","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ijid.2026.108581_bib0024","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1038\/s41467-025-60598-4","article-title":"Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial","volume":"16","author":"Weiner","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijid.2026.108581_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2024.199442","article-title":"Safety and tolerability of bronchoscopic and nebulised administration of bacteriophage","volume":"348","author":"Singh","year":"2024","journal-title":"Virus Res"},{"issue":"9","key":"10.1016\/j.ijid.2026.108581_bib0026","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1111\/ajt.15503","article-title":"Early clinical experience of bacteriophage therapy in 3 lung transplant recipients","volume":"19","author":"Aslam","year":"2019","journal-title":"Am J Transpl J Am Soc Transpl Am Soc Transpl Surg"},{"issue":"11","key":"10.1016\/j.ijid.2026.108581_bib0027","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/ppul.24945","article-title":"Combining bacteriophages with cefiderocol and meropenem\/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient","volume":"55","author":"Gainey","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ijid.2026.108581_bib0028","article-title":"Bacteriophage therapy for Pan-drug-resistant Pseudomonas aeruginosa in two persons with cystic fibrosis","volume":"11","author":"Hahn","year":"2023","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"9","key":"10.1016\/j.ijid.2026.108581_bib0029","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.resmic.2018.05.001","article-title":"Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report","volume":"169","author":"Hoyle","year":"2018","journal-title":"Res Microbiol"},{"issue":"2","key":"10.1016\/j.ijid.2026.108581_bib0030","article-title":"Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug-resistant Burkholderia multivorans","volume":"25","author":"Haidar","year":"2023","journal-title":"Transpl Infect Dis J Transpl Soc"},{"issue":"5","key":"10.1016\/j.ijid.2026.108581_bib0031","doi-asserted-by":"crossref","DOI":"10.1128\/asmcr.00058-24","article-title":"Resolution of acute rejection in a bilateral double-lung transplanted cystic fibrosis patient following phage intervention","volume":"1","author":"Pardo-Freire","year":"2025","journal-title":"ASM Case Rep"},{"issue":"1","key":"10.1016\/j.ijid.2026.108581_bib0032","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/v13010060","article-title":"A case of phage therapy against pandrug-resistant achromobacter xylosoxidans in a 12-year-old lung-transplanted cystic fibrosis patient","volume":"13","author":"Lebeaux","year":"2021","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.ijid.2026.108581_bib0033","article-title":"A case series of emergency investigational new drug applications for bacteriophages treating recalcitrant multi-drug resistant bacterial infections: confirmed safety and a signal of efficacy","volume":"5","author":"Duplessis","year":"2019","journal-title":"J intensive crit care"},{"issue":"4","key":"10.1016\/j.ijid.2026.108581_bib0034","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s15010-019-01319-0","article-title":"Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient","volume":"47","author":"Law","year":"2019","journal-title":"Infection"},{"issue":"9","key":"10.1016\/j.ijid.2026.108581_bib0035","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/INF.0000000000004000","article-title":"Bacteriophage therapy of multidrug-resistant Achromobacter in an 11-year-old boy with cystic fibrosis assessed by metagenome analysis","volume":"42","author":"Bradley","year":"2023","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.ijid.2026.108581_bib0036","first-page":"413","article-title":"Inhaled bacteriophage therapy for multi-drug resistant Achromobacter","volume":"95","author":"Winzig","year":"2022","journal-title":"Yale J Biol Med"},{"issue":"11","key":"10.1016\/j.ijid.2026.108581_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.04.024","article-title":"Host and pathogen response to bacteriophage engineered against mycobacterium abscessus lung infection","volume":"185","author":"Nick","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ijid.2026.108581_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2026.115005","article-title":"Successful bacteriophage treatment of a recalcitrant intra-abdominal infection caused by multidrug-resistant Pseudomonas aeruginosa in a 2-year-old child","volume":"291","author":"Malhotra","year":"2026","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.ijid.2026.108581_bib0039","first-page":"124","article-title":"Phage therapy analysis of effectiveness in comorbid patients with wounds and surgical infections of various etiology based on the results of a comparative clinical study","author":"Paskhalova","year":"2025","journal-title":"Khirurgiia (Mosk)"},{"issue":"3","key":"10.1016\/j.ijid.2026.108581_bib0040","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1473-3099(20)30330-3","article-title":"Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial","volume":"21","author":"Leitner","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.ijid.2026.108581_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.11.018","article-title":"Randomized double-blind study on safety and tolerability of TP-102 phage cocktail in patients with infected and non-infected diabetic foot ulcers","volume":"6","author":"Nir-Paz","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.ijid.2026.108581_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114759","article-title":"Bactericidal synergism between phage and antibiotics: a combination strategy to target multidrug-resistant Klebsiella pneumoniae in vitro and in vivo","volume":"213","author":"Wang","year":"2025","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ijid.2026.108581_bib0043","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s41591-021-01403-9","article-title":"Potent antibody- mediated neutralization limits bacteriophage treatment of a pulmonary mycobacterium abscessus infection","volume":"27","author":"Dedrick","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ijid.2026.108581_bib0044","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1128\/AEM.02850-14","article-title":"Burkholderia cepacia complex phage-antibiotic synergy (PAS): antibiotics stimulate lytic phage activity","volume":"81","author":"Kamal","year":"2015","journal-title":"Appl Env Microbiol"},{"issue":"3","key":"10.1016\/j.ijid.2026.108581_bib0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1208\/s12248-019-0315-0","article-title":"Bacteriophage PEV20 and ciprofloxacin combination treatment enhances removal of Pseudomonas aeruginosa biofilm isolated from cystic fibrosis and wound patients","volume":"21","author":"Chang","year":"2019","journal-title":"AAPS J"},{"issue":"4","key":"10.1016\/j.ijid.2026.108581_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2025.107571","article-title":"Bacteriophage-enhanced doxycycline activity against Escherichia coli in chronic bacterial prostatitis","volume":"66","author":"Cesta","year":"2025","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2026.108581_bib0047","unstructured":"Novel nebulized phage cocktail in CF patients with chronic P. aeruginosa pulmonary infection: a Ph1b\/2a randomized, double-blind, placebo-controlled trial | request PDF. ResearchGate [Internet]. [accessed September 14 2025]; Available from: https:\/\/www.researchgate.net\/publication\/385614508_Novel_nebulized_phage_cocktail_in_CF_patients_with_chronic_P_aeruginosa_pulmonary_infection_a_Ph1b2a_randomized_double-blind_placebo-controlled_trial."},{"key":"10.1016\/j.ijid.2026.108581_bib0048","unstructured":"Armata Pharmaceuticals, Inc. A phase 1b\/2a, multi-center, double-blind, randomized, placebo-controlled, single and multiple ascending dose study to evaluate the safety and tolerability of AP-PA02 multi-phage therapeutic candidate for inhalation in subjects with cystic fibrosis and chronic pulmonary Pseudomonas Aeruginosa (Pa) infection. clinicaltrials.gov; 2024 [accessed September 14 2025]. Report No.: NCT04596319. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04596319"},{"key":"10.1016\/j.ijid.2026.108581_bib0049","unstructured":"Armata Pharmaceuticals, Inc. A phase 2, multi-center, double-blind, randomized, placebo controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 multi-phage therapeutic in subjects with non-cystic fibrosis bronchiectasis and chronic pulmonary Pseudomonas Aeruginosa infection. clinicaltrials.gov; 2024 [accessed September 14 2025]. Report No.: NCT05616221. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05616221"},{"issue":"4","key":"10.1016\/j.ijid.2026.108581_bib0050","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jcf.2025.03.669","article-title":"Trial design of bacteriophage therapy for nontuberculous mycobacteria pulmonary disease in cystic fibrosis: the POSTSTAMP study","volume":"24","author":"Nick","year":"2025","journal-title":"J Cyst Fibros J Eur Cyst Fibros Soc"},{"issue":"5","key":"10.1016\/j.ijid.2026.108581_bib0051","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1751-7915.2011.00259.x","article-title":"Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens","volume":"4","author":"Kvachadze","year":"2011","journal-title":"Microb Biotechnol"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197122600216X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197122600216X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T20:29:18Z","timestamp":1778099358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S120197122600216X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":51,"alternative-id":["S120197122600216X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108581","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phage therapy in people with cystic fibrosis: A systematic review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108581","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108581"}}